enVVeno Medical Corp
NASDAQ:NVNO

Watchlist Manager
enVVeno Medical Corp Logo
enVVeno Medical Corp
NASDAQ:NVNO
Watchlist
Price: 10.51 USD -10.09% Market Closed
Market Cap: $212.5m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
enVVeno Medical Corp
NASDAQ:NVNO
212.5m USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.6B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
186.9B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
138.7B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.1B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
130.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.5B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.4B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.9B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

enVVeno Medical Corp
Glance View

Market Cap
212.5m USD
Industry
Health Care

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

NVNO Intrinsic Value
1.39 USD
Overvaluation 87%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top